Site Search

>> Advanced Search

Free Newsletter

  Email address:
   

In the News
Greg Scott presents industry update during JPMorgan
>> View video…

>> More News...

Now on Twitter!
 

Twitter ID: ChinaBio

China Aoxing Given SFDA OK for Angina Drug

publication date: May 4, 2009
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.

China Aoxing Pharmaceutical Company (中国奥星药业) has received an SFDA production license for Isosorbide Mononitrate Injection, a vasodilator, for treatment of angina pectoris, myocardial infarction, chronic congestive heart failure, pulmonary hypertension and related coronary artery disease. China Aoxing, which focuses on pain medications, plans to begin selling its newest product to hospitals in the second half of 2009. More details...

Stock Symbol: (OTCBB: CAXG)




Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...


Login

 

 
   
ChinaBio® Events
April 14, 2010
Guangzhou, China

SEED Final Competion and Award Ceremony
April 23, 2010
Shanghai, China
Suzhou, China
June 23-24, 2010
 
Partner Events

China 2010 Pharmaceutical R&D Summit
Shanghai, China
April 5-8, 2010

Our Partners
Annual Sponsors
 
Official Partners
 
Supporting Partners
 
Media Partners